Understanding the European Medical Device Regulation (EU MDR)
The European Medical Device Regulation (EU MDR) has brought significant changes to the medical device industry, ensuring stricter safety and performance standards. Compared to the previous EU Medical Device Directive (MDD), the new medical device regulation enforces rigorous clinical evaluation requirements, enhanced post-market surveillance, and stricter conformity assessments.
Manufacturers must now provide substantial clinical evidence demonstrating safety, performance, and clinical benefits before receiving CE certification. The EU MDR also strengthens patient safety by implementing unique device identification (UDI) and improving transparency through EUDAMED. As compliance deadlines approach, companies must prioritize regulatory strategies to meet evolving medical device regulation requirements.
How MDR Impacts Medical Device Companies
The transition from the European Medical Device Directive (MDD) to the European Medical Device Regulation (EU MDR) has introduced stringent requirements for medical device companies. One of the most significant changes is the EU medical device registration process, which now demands comprehensive clinical data, stricter post-market surveillance (PMS), and enhanced traceability.
Companies must conduct conformity assessments for all medical devices, ensuring compliance with the updated classification rules. The clinical evaluation process now requires stronger evidence, making it difficult to demonstrate equivalence with existing CE-marked devices. Additionally, manufacturers must actively collect Post-Market Clinical Follow-Up (PMCF) data and submit Periodic Safety Update Reports (PSURs) for Class II and III devices.
Failure to comply with EU MDR may result in market withdrawal, impacting both business operations and patient safety. Thus, it is crucial for manufacturers to stay updated with evolving medical device regulations, streamline regulatory documentation, and invest in robust clinical data management systems to ensure seamless market access and long-term compliance.
Impact of MDR on Your Device
As of May 25th 2017, the European Medical Device Regulation (EU MDR) has replaced the long-standing Medical Device Directive (MDD). The impact of the Medical Device Regulation (MDR) to the medical device industry is substantial as it requires the re-classification and re-registration of all medical devices currently on the market.
Impact
1)More medical devices will require clinical investigation;
2)Equivalence will be harder to demonstrate;
3)The level of evidence required for medical device studies will be higher
4)There will be more focus on post-market surveillance.
What does it mean for you
It also means you will need to do a conformity assessment for all your devices currently on the market, be it a syringe or a pacemaker, or remove the product from the market. Additionally, more products will be considered to be a medical device.
Impact Solution
Make sure you are well informed about the new classifications and corresponding clinical requirements of your products as per new Medical Device Regulation (MDR).
In addition, the manufacturer needs to demonstrate it has access to the equivalent device data, which significantly limits its usability. These criteria were also added in the most recent revision of the guidance on the clinical evaluation(MEDDEV 2.7.1 rev.4).
Where medical device clinical studies previously aimed to demonstrate safety and performance, studies under the EU MDR will now also need to show the clinical benefit to patients. This means that clinical trials should be designed with completely different end-points, more complex study setups, and potentially larger sample sizes. Additionally, clinical investigation plans should include details on prevention of scientific bias.
A PMS system shall be used to actively gather and analyse data on the quality, performance, and safety of the device throughout its lifetime. The system should be based on a PMS plan and to be outputted in a report. In addition Class II and III devices should prepare yearly for periodic safety update reports (PSUR) containing the analyses of the PMS data gathered, including data from post-market clinical follow-up.
Regulation (EU MDR) is necessary, particularly in a sector, like the Medical device sector, which exposes countries and people to a risk.
Clinical Data Requirements Under MDR
The MDR regulation has introduced stringent requirements for clinical data collection to ensure the safety and performance of medical devices. Under the EU regulation for medical devices, manufacturers must provide robust clinical evidence demonstrating not only the safety and performance of their devices but also their clinical benefits. This requires compliance with ISO 14155 and Good Clinical Practice (GCP) standards.
Additionally, the need for Post-Market Clinical Follow-up (PMCF) and Periodic Safety Update Reports (PSURs) has intensified, requiring manufacturers to continuously gather and analyze real-world data. Ensuring compliance with these new clinical requirements is essential for maintaining market access in the EU under the Medical Device Regulation (MDR) framework.
Clinical Data Requirements Under EU MDR
The EU MDR significantly increases clinical data requirements for medical device manufacturers. Traditionally, companies have relied on literature reviews and equivalence routes to demonstrate the clinical safety and performance of their devices by comparing them with existing CE-marked devices available on the market.
Under the MDR, manufacturers are expected to generate and maintain stronger clinical evidence throughout the device lifecycle. Clinical data collection must comply with Good Clinical Practice (GCP) requirements, as outlined in ISO 14155.
Key GCP Requirements
- Informed consent from study participants
- Protection of patient privacy and confidentiality
- Safe and compliant data processing
- Ethical conduct of clinical investigations
These requirements have further increased the importance of:
- Post-Market Clinical Follow-up (PMCF)
- Post-Market Surveillance (PMS)
- Periodic Safety Update Reports (PSUR)
Key Changes Introduced by EU MDR
The implementation of the EU MDR introduces several significant regulatory changes:
Stricter Regulatory Oversight
- Stronger pre-market control of high-risk medical devices at the EU level
- Enhanced requirements for clinical evidence and clinical evaluations
- Reinforced rules for clinical investigations and performance studies
Expanded Scope
- Inclusion of certain aesthetic products that have similar characteristics and risk profiles as medical devices
New Risk Classification System
- Updated risk classification framework for diagnostic medical devices based on internationally recognized guidance
Improved Transparency
- Establishment of EUDAMED, the comprehensive European database for medical devices
- Greater visibility of device and manufacturer information across the EU
Enhanced Traceability
- Improved device traceability throughout the entire supply chain, from manufacturer to end user
- Mandatory Unique Device Identification (UDI) system
Patient Safety Enhancements
- Requirement for implant cards to be provided to patients receiving implantable medical devices
- Better access to device information and safety data
Stronger Post-Market Requirements
- Manufacturers must actively collect and analyze real-world data on device performance and safety
- Increased emphasis on PMS, PMCF, vigilance activities, and continuous monitoring
Better Coordination Across EU Member States
Previously, different European countries interpreted and implemented medical device directives differently. The EU MDR establishes a more harmonized regulatory framework, improving consistency and coordination across all Member States.
Navigating MDR Compliance
Implementing the EU MDR can be complex and challenging. It is essential for manufacturers to regularly assess their compliance strategy, clinical evidence, and post-market processes to ensure alignment with the latest regulatory requirements and expectations.
